Background: Immune suppression in the tumour microenvironment remains a major limitation to successful immunotherapy of cancer. In the current study, we analysed whether the natural killer T cell-activating glycolipid a-galactosylceramide could overcome immune suppression and improve vaccination against metastatic breast cancer.
Breast cancer is the most common cancer among women worldwide, and B30% of cases progress to metastatic disease, which is difficult or impossible to treat effectively (Youlden et al, 2012) . Current treatment options for metastatic cancer include surgery followed by chemotherapy or radiation, or other adjuvant therapy (Cardoso et al, 2012) . Despite aggressive treatment, elimination of metastases or residual tumour cells after initial treatment is often incomplete, and removal of residual disease by chemotherapy is prevented by chemoresistance (Gonzalez-Angulo et al, 2007) . This underlines the urgent need for new effective therapies against metastatic disease.
It has been shown in mice and humans that vaccines can have a favourable effect on metastases (Niethammer et al, 2002; Marchand et al, 2003; Kruit et al, 2005; Kim et al, 2008) but that vaccine efficacy is strongly reduced by immune suppression in the tumour microenvironment (TME; Gajewski et al, 2006) . In a previous study, we developed a vaccine based on a non-pathogenic strain of Listeria monocytogenes (LM) expressing the tumourassociated antigen (TAA) Mage-b (LM-Mb; Kim et al, 2008) . Listeria monocytogenes is an intracellular bacterium that has the capacity to deliver antigens through infection into antigenpresenting cells (APCs) such as dendritic cells (DCs), monocytes and macrophages with high efficiency (Paterson and Maciag, 2005) . We have also demonstrated that LM infects tumour cells, which can lead to cytolytic effects through a mechanism involving induction of high levels of reactive oxygen species, and sensitises the infected tumour cells for recognition by LM-specific CD8 þ T cells (Kim et al, 2009) . When administered prior to tumour establishment in an aggressive mouse model of metastatic breast cancer (4T1), LM-Mb treatment resulted in strong CD8
þ T-cell responses to both Mage-b and LM and an almost complete elimination of metastatic disease (Kim et al, 2008) . However, when administered in a therapeutic setting (i.e., after establishment of primary 4T1 tumours), LM-Mb treatment was only moderately effective against metastatic breast cancer, and induced relatively weak CD8
þ T-cell responses to Mage-b, due to strong immune suppression in the TME (Kim et al, 2009) .
To overcome the immune suppression that is characteristic of tumour-bearing hosts, immunologic adjuvants that can promote robust immune responses and augment the effects of therapeutic vaccines are greatly needed. Glycolipids of the a-galactosylceramide family (aGC) represent one potentially useful class of adjuvants that have shown promise in preclinical studies for immunotherapy of cancers (Metelitsa, 2011; Yamasaki et al, 2011) . These glycolipids mediate their effects on the immune system by binding to an MHC class I-like molecule called CD1d, creating a complex that is recognised by a population of conserved effector lymphocytes known as natural killer T (NKT) cells (Bendelac et al, 2007) . Formation of intracellular complexes of CD1d with aGC in APCs initiates rapid NKT-cell activation (Bendelac et al, 2007) , resulting in the production of Th1-associated cytokines such as IFNg and IL-12p70, maturation of CD8a þ DCs in the lymph nodes and subsequent activation of NK and conventional T cells (Hermans et al, 2003; Venkataswamy et al, 2009 ). This cascade of immune reactions that is initiated by NKT cells in response to aGC has been shown in mouse models to generate innate and adaptive immunity against a wide range of cancers and infections (Brigl et al, 2003; Behar and Porcelli, 2007; Bendelac et al, 2007) .
Based on these observations we hypothesised that addition of aGC to LM-Mb vaccine could improve therapeutic efficacy, in part through enhancement of specific T cell responses to Mage-b. When these two agents were used as combination therapy in the 4T1 model, aGC significantly improved the therapeutic vaccine efficacy of LM-Mb as demonstrated by the almost complete elimination of the metastases. However, the administration of these two agents sequentially caused severe and in some cases fatal toxicity to the liver, leading us to explore other novel strategies. Drawing on previous experience using direct incorporation of relatively low doses of aGC into live Mycobacterium bovis BCG to improve vaccine efficacy (Venkataswamy et al, 2009) , we developed a similar approach for direct incorporation of the glycolipid into live LM organisms. This generated a vaccine that was equally effective against metastatic breast cancer compared to sequential administration of LM-Mb and aGC as separate agents, but without any apparent toxicity. The powerful anti-metastatic effect of vaccination with LM-Mb modified by direct incorporation of aGC correlated with an increase in the frequency of splenic NKT cells, and improved responses of Mage-b-specific CD8 þ T and NK cells. This approach may provide a basis for new strategies to safely improve vaccine efficacy against metastatic cancer through augmentation of multiple innate and adaptive immune mechanisms.
MATERIALS AND METHODS
Mice. Normal female BALB/c mice aged 3 months were obtained from Charles River Laboratories and maintained in the animal facility of Albert Einstein College of Medicine according to the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care, and according the guidelines of the Albert Einstein Institute for Animal Studies. All mice were kept under biosafety level 2 conditions, as required for Listeria monocytogenes.
Cells, cell culture and plasmids. The 4T1 cell line, derived from a spontaneous mammary carcinoma in a BALB/c mouse (Aslakson and Miller, 1992) , was cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 1 mM mixed non-essential amino acids, 2 mM L-glutamine, insulin (0.5 USP units ml À 1 ), penicillin (100 units ml À 1 ) and streptomycin (100 mg ml À 1 ). The DNA plasmids pcDNA3.1-Mage-b (Sypniewska et al, 2005) , pcDNA3.1-LacZ (Invitrogen, Grand Island, NY, USA) and pCMV-GM-CSF (Chambers and Johnston, 2003) were purified using the Endo-Free Mega kit from Qiagen (Valencia, CA, USA).
LM-based vaccine. The LM-Mb strain was developed in an earlier study (Kim et al, 2008) . This was constructed in the prfA-negative XFL-7 strain (referred to as LM in this study), which lacks the positive regulatory factor A that is a central mediator of virulence (Singh et al, 2005) . The vaccine strain was transformed with LM plasmid pGG-34, which encodes prfA and amino acids 311-660 of murine Mage-b fused to a non-cytolytic form of listeriolysin O (Gunn et al, 2001; Kim et al, 2008) . Complementation of prfA expression by the plasmid does not fully restore virulence, but enforces retention of the plasmid during infection (Gunn et al, 2001; Singh et al, 2005) .
Incorporation of aGC into live LM-Mb. The aGC used in this study ((2S, 3S, 4R)-1-O-(a-D-galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol), also known in previous studies as KRN7000 or aGalCer-C26:0, was synthesised as previously described (Yu et al, 2005) , and stored as solvent-free aliquots in glass vials at À 201C. The glycolipid was reconstituted either in 100% dimethylsulphoxide (DMSO) at 100 mM for in vitro studies, or in aqueous vehicle consisting of PBS with 0.05% Tween 20 (Life Technologies, Grand Island, NY, USA) and 0.1% DMSO at 500 mM for in vivo studies. The incorporation of aGC into live LM was performed using a method similar to that described previously for M. bovis BCG (Venkataswamy et al, 2009) . Briefly, aGC was solubilised at a concentration of 2.3 mM in glass vials by addition of warm (371C) brain-heart infusion medium containing 5% tyloxapol, followed by sonication for 5 min, heating at 801C for 2 min and vortexing for 1 min. Then, 450 ml of the 2.3 mM glycolipid solution was immediately diluted into 50 ml of warm BHI to give the required final concentrations of 20 nM glycolipid and 0.05% tyloxapol, and this was inoculated with 500 ml of a LM-Mb mid-log phase culture (OD 600 0.5-0.8). Following incubation for 4-6 h at 371C to reach mid-log phase (OD 600 0.5-1.0), the bacterial culture was then immediately aliquoted in 1 ml vials and frozen at À 801C. For subsequent use, the bacteria were thawed, harvested by centrifugation, washed three times with saline and resuspended in saline for injection. In order to determine the incorporation of aGC into LM, we measured the ability of the bacteria to activate an iNKT-cell hybridoma as described in Supplementary Figure S1 .
Tumour challenge and immunotherapy regimens. Mice were challenged with 10 4 4T1 cells injected into the mammary fat pad as described previously (Kim et al, 2008) , and then treated using therapeutic regimens to compare the effects of combined LM-Mb and aGC treatment either as separate agents or as glycolipid-modified bacteria. Initial pilot studies showed that when these two agents were administered separately, anti-metastatic effects were greater when LM-Mb treatment was given prior to a series of injections of aGC, as opposed to the reverse order. Moreover, when LM-Mb and aGC were administered at the same time points, the anti-metastatic effect was less compared to LM-Mb and aGC administered sequentially, and animals developed severe liver toxicity (data not shown). Based on these observations we administered LM-Mb first followed by aGC in all subsequent experiments when used as separate agents. The first protocol consisted of three therapeutic immunisations with LM-Mb followed by three injections of aGC. Mice received 10 4 4T1 tumour cells in the mammary fat pad on day 0, followed by three i.p. injections of LM-Mb or LM (10 4 CFU), or saline on days 3, 6 and 9, and then three i.p. injections of aGC (100 ng in 200 ml vehicle) i.p. on days 14, 15 and 16. The second protocol consisted of five therapeutic immunisations with LM-Mb modified by direct incorporation of aGC (I-aGC-LM-Mb). Mice received 10 4 4T1 tumour cells in the mammary fat pad on day 0, followed by i.p. injections of 10 4 CFU of I-aGC-LM-Mb on days 3, 6, 9, 12 and 15. All mice were euthanised for the analysis of metastatic disease and immunology on day 18. The total number of metastases per mouse was determined as previously described (Kim et al, 2008) . For studies carried out to determine effects on survival, mice were maintained until they succumbed spontaneously, or were terminated upon appearance of severe pre-morbid symptoms requiring euthanasia as specified by our approved animal use protocol.
Activation of iNKT cells in vivo. BALB/c mice were injected i.p. with the inert vehicle (PBS plus 0.05% Tween 20 and 0.1% DMSO), 10 4 CFU LM, 10 4 CFU I-aGC-LM or 4 nmoles of free aGC. Sera were assayed at the indicated times for IL-4, and IFNg by capture ELISA as previously described (Yu et al, 2005) . Alternatively, BALB/c mice receiving 4T1 tumour cells and therapeutic immunisations with LM-Mb or I-aGC-LM-Mb (see above) were injected with 4 nmoles of free aGC 15 days after the injection of tumour cells. After the indicated times, splenocyte single-cell suspensions were obtained and stained with anti-mouse TCR-FITC (clone H57-597, BD Biosciences, San Jose, CA, USA) and aGCloaded mouse CD1d tetramers-APC, prepared as previously described (Venkataswamy et al, 2009 ). Samples were acquired using a LSR II Flow Cytometer (BD Biosciences) and analysed using FlowJo software (TreeStar Software, Ashland, OR, USA).
Flow cytometry analyses. Cells were isolated from blood as described previously (Kim et al, 2008; Castro et al, 2009) . Briefly, red blood cells were lysed according standard protocols, and the remaining leukocyte population was used for analysis. Cells were first incubated with Golgi-Plug for 6 h (BD Biosciences), then with an Fc blocker (mAb 2.4G2, anti-CD16/CD32), and finally with specific fluorochrome-conjugated antibodies for the identification of different cell types. Anti-CD8a-PE (clone 53-6.7) antibodies were used to identify CD8 T cells, and anti-CD45-APC antibody (clone 30-F11) to identify the leucocyte population in tumour cell suspensions. To detect the production of intracellular cytokines, cell suspensions were processed using the BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions, and stained using antibodies to IFNg (clone XMG1.2). Appropriate isotype controls were used for each sample. All antibodies were purchased from BD Biosciences. For most samples, data of 1.5 Â 10 5 and 3 Â 10 5 cells were acquired using a FACSCalibur flow cytometer (BD Biosciences). However, in some cases where noted with samples derived from small tumours, limited cell numbers allowed acquisition of only10 4 cells. Cell debris and dead cells were excluded from the analyses based on forward and side scatter signals, and used Fixable Blue or Green Live/Dead Cell Stain kit (Invitrogen). All data analyses were done using FlowJo software (TreeStar).
ELISPOT. Spleen cells were isolated from vaccinated and control mice with 4T1 tumours and analysed for T cell responses to Mageb-and NK-cell responses to LM by ELISPOT as described previously (Kim et al, 2008; Chandra et al, 2013) . To detect Mageb-specific immune responses, 4 Â 10 5 spleen cells of vaccinated or control mice were transfected with plasmids pcDNA3.1-Mage-b and pCMV-GM-CSF (1 mg of each plasmid per 5 Â 10 6 spleen cells) using Lipofectamine 2000 (Life Technologies), as described previously (Kim et al, 2008) . Expression of Mage-b by the transfected spleen cells was verified by RT-PCR followed by Southern blotting (Supplementary Figure S2) . To detect LMinduced NK cell responses, 2 Â 10 5 spleen cells were infected with 2 Â 10 5 CFU of LM for 1 h, and subsequently treated with gentamicin (50 mg ml À 1 ) until the end of restimulation (72 h). After 72 h, the frequency of IFNg-producing cells was determined by ELISPOT according to standard protocols (BD Biosciences), using an ELISPOT reader (CTL Immunospot S4 analyzer, Cellular Technology Ltd., Cleveland, OH, USA). To determine the CD8 þ T-cell or NK-cell component of the responses, spleen cells were depleted of CD8 T cells using anti-CD8a (Clone 53-6.7)-conjugated magnetic beads, or depleted of NK cells using antiCD49b (Clone DX5)-conjugated magnetic beads according to the manufacturer's instructions (Miltenyi, Auburn, CA, USA).
Assessment of toxicity. Liver toxicity was assessed by visual inspection after killing the mice, and a numerical grade was assigned corresponding to the size and number of visible necrotic plaques. The toxicity was graded as follows: T0 ¼ no lesions (normal appearance); T1 ¼ uniform light discolouration and firmness; T2 ¼ white plaques visible covering B5% of the liver surface; T3 ¼ white plaques covering B10% of liver surface; T4 ¼ white plaques covering up to B30% of liver surface; and T5 ¼ white plaques covering X30% of liver surface. Haematoxylin and eosin (H&E) staining of thin sections of livers was also done to confirm the presence and extent of hepatic inflammation and necrosis. Briefly, liver tissues were fixed in 10% formaldehyde for 48 h, and then kept in 70% ethanol until use. Sections of 1 mm thickness were stained with H&E, and analysed for pathological damage by light microscopy. All pathological analyses were performed by a trained veterinary pathologist. Survival was followed for up to 18 days, and survival curves plotted for the various treatment groups.
Statistical analysis. Effects of treatments on tumour growth, metastasis and immune responses were analysed using the MannWhitney test, Unpaired t-test or ANOVA with Sidak post-test for multiple comparisons as indicated. Survival studies were analysed with the Mantel-Cox test. Values of Po0.05 were considered statistically significant.
RESULTS
Efficacy of combination therapy with LM-Mb and aGC in metastatic breast cancer. The therapeutic effect of combining the LM-Mb vaccine with aGC treatment or aGC physically incorporated into live LM-Mb vaccine on metastatic breast cancer was assessed in the 4T1 mouse tumour model. Mice treated with unmodified LM showed marked reduction in metastases when killed at day 18 after initial tumour implantation ( Figure 1A) , consistent with previous studies showing that this treatment induces a variety of tumoricidal mechanisms (Kim et al, 2009 ). An improved anti-metastatic effect was observed with LM-Mb compared to LM, suggesting an effect of Mage-b-specific immunity, and a similar level of anti-metastatic activity was observed with administration of aGC as a single agent. Strikingly, the combination of aGC with LM-Mb, either as a separately administered agent (LM-Mb þ aGC) or by direct incorporation of the glycolipid into the live bacteria (I-aGC-LM-Mb), gave a significantly better anti-metastatic effect compared to LM-Mb alone or aGC alone ( Figure 1A) . Both of the regimens using combined LM-Mb and aGC treatment reduced the number of macroscopically visible metastases nearly to zero, with only a rare nodule being detected in these mice. The number of metastases were reduced by I-aGC-LM-Mb in all tissues/organs compared to the saline group (MLN, spleen, kidney, liver and diaphragm), but most dramatically in the MLN (Supplementary Table S1 ). Significant reductions in the weights of primary tumours were also observed in all treatment groups compared to the saline group (with an exception for LM), although combination treatment did not show significant improvement over single-agent treatment in this parameter ( Figure 1B ).
Direct incorporation of aGC into LM-Mb avoids severe toxicity. Although aGC was equally efficacious in reducing metastases when administered as a free glycolipid following LMMb treatment or simultaneously using the direct incorporation approach, analysis of survival of treated mice revealed a striking difference between these two approaches. This was first examined in a short-term survival study in which mice receiving various therapies were observed for 18 days following implantation of 4T1 cells in the mammary fat pad. Whereas all sham-treated 4T1 bearing mice (i.e., saline injections only) survived at least 18 days from the time of tumour initiation, we observed a significant fatality rate starting around day 11 in animals treated with the sequential administration of LM-Mb and aGC as separate agents. In contrast, no deaths were observed over this time period in any of the other treatment groups, including those which received LMMb with directly incorporated aGC (I-aGC-LM-Mb; Figure 2A ). We then carried out a second more extended survival study to compare time to death in 4T1 tumour-bearing mice receiving therapeutic vaccinations with I-aGC-LM-Mb vs mice receiving only saline injections. Although mice that received only sham immunisations with saline all succumbed by day 20, mice that received I-aGC-LM-Mb all survived past day 20 and showed a significant extension (30%) of overall survival ( Figure 2B ). This extension of survival was consistent with the marked antimetastatic effect and low toxicity of the I-aGC-LM-Mb treatment.
The apparent toxicity leading to accelerate death in animals receiving the separately injected LM-Mb and aGC regimen was investigated by necropsy performed on animals killed at day 18. Focal areas of hepatic necrosis were found and verified by histologic studies of thin sections of the liver ( Figure 3A) . Such foci were also observed with lower frequency and smaller size in mice that received aGC alone, but not at all in animals that were treated with I-aGC-LM-Mb or LM-Mb alone ( Figure 3B ).
Activation of NKT cells in spleens of 4T1 tumour-bearing mice that received I-aGC-LM-Mb. To determine whether LM bacteria modified by direct incorporation of aGC could activate NKT cells in vivo, we assessed the rapid production of IFNg and IL-4, two cytokines that are characteristically for NKT-cell activation. For this purpose we injected naive mice once with LM, aGC or LM modified by direct incorporation of aGC (I-aGC-LM) and obtained serum samples at various time points after injection to determine cytokine levels. (The slower adaptive responses to Mb is irrelevant in this analysis of rapid innate-like NKT-cell responses.) Previous studies have shown that aGC administered as a free glycolipid induces the production of IFNg and IL-4 that peak in the serum at B10-12 and 2 h, respectively (Venkataswamy et al, 2009) . Infection with LM also induces the rapid production of IFNg in naive mice by multiple cell types, including NK, NKT and CD8 þ T cells (North and Conlan, 1998; Brigl et al, 2003; Soudja et al, 2012) . We found that I-aGC-LM stimulated a serum IFNg response that was apparent at 10 h, and peaked at 24 h. In contrast, LM infection generated a large transient serum IFNg response, which was first detected at 24 h ( Figure 4A ). The accelerated IFNg production seen with I-aGC-LM was consistent with direct NKTcell activation by the aGC incorporated into the bacteria. Also supporting the conclusion that NKT cells were directly activated, we observed a significant IL-4 response at 2 h after injection of I-aGC-LM, whereas LM alone did not induce detectable IL-4 ( Figure 4B ).
To confirm that NKT cells were rapidly activated by treatment with I-aGC-LM-Mb in tumour-bearing mice in vivo, we analysed the percentages of NKT cells in the spleens of mice with 4T1 tumours and metastases that were therapeutically immunised with I-aGC-LM-Mb using CD1d tetramers loaded with aGC. The percentage of NKT cells stained with the tetramer in the spleens of tumour-bearing mice that had received five therapeutic treatments with I-aGC-LM-Mb was either unchanged or slightly increased
Number of mice * Figure 3 . Hepatotoxicity of aGC administered as a separate agent but not when incorporated into LM-Mb. Representative micrographs of H&E stained sections from the livers of mice 4T1 tumour-bearing mice that received I-aGC-LM-Mb (left) or LM-Mb þ aGC (right) as described in Figure 1 , and killed on day 18 (A). Low power views (top) show normal appearance of liver tissue typical for I-aGC-LM-Mb-treated mice, and foci of necrosis and inflammatory cells that were common in mice receiving LM-Mb þ aGC. Higher magnification views of the boxed areas are shown in the lower panels, with an area of necrosis marked by the asterisk and arrows indicating leukocyte infiltrates for the LM-Mb þ aGC sample. Summary of semiquantitative grading of toxicity based on gross liver pathology (B). BALB/c mice were challenged with 4T1 tumour cells and immunised therapeutically i.p. with saline or the single or combination regimens as described in Figure 1 . Toxicity was graded in each mouse by visual inspection of livers at necropsy using a scale from T0 to T5 as described in Materials and Methods. This experiment was repeated three times with N ¼ 5 mice per group and the results of all experiments are combined in the graph shown.
compared to saline or LM-treated controls at 0 h post aGC injection ( Figure 5A and B), while tetramer binding of NKT cells showed a transient decrease in the spleen at 12 h, followed by a rebound to greater than baseline levels at 72 h ( Figure 5A and B) . This was consistent with the normal activation pattern observed for intact NKT-cell populations in healthy naive mice, which is characterised by rapid TCR downmodulation leading to loss of tetramer staining at earlier time points, followed by TCR reexpression and proliferative expansion of the tetramer staining population by 72 h (Wilson et al, 2003) . In fact, animals that had received prior treatment with either LM-Mb or I-aGC-LM-Mb showed significantly increased expansion of NKT cells at 72 h after subsequent injection of free aGC, with I-aGC-LM-Mb showing the greater effect ( Figure 5A and B) . In summary, NKT-cell activation by repeated I-aGC-LM-Mb treatments did not lead to either depletion or anergy of NKT cells in vivo, and may actually have primed NKT cells to respond more vigourously to subsequent stimulation.
Improved T cell and NK-cell responses in mice vaccinated with I-aGC-LM-Mb. The activation of NKT cells has been frequently shown to lead secondarily to increased CD8 þ T-cell cross-priming and to NK-cell activation (Hermans et al, 2003; Venkataswamy et al, 2009) . Given that NKT-cell activation was augmented by treatment of tumour-bearing mice with I-aGC-LM-Mb, we analysed whether this treatment could also enhance CD8 T cell (CD8a þ ) and NK-cell (CD49b/DX5 þ ) responses using the production of IFNg by these cells as an activation marker. First, we analysed antigen-dependent recall responses to Mage-b in the spleens of I-aGC-LM-Mb-treated and control mice upon restimulation with Mage-b in vitro using IFNg ELISPOT assays. This showed significantly higher numbers of IFNg secreting cells in response to stimulation ex vivo by expression of Mage-b by plasmid transfection in the spleens of mice treated with I-aGC-LM-Mb compared to the control mice treated with LM-Mb, aGC or saline ( Figure 6A ). These responses were substantially diminished following depletion using anti-CD8a-conjugated magnetic beads. Very low numbers of IFNg-producing cells were observed after restimulation by transfecting a plasmid encoding only a control protein, lacZ (Supplementary Figure S3) , demonstrating the antigen specificity of the restimulation assay. Although NK cells and a subset of DCs express low levels of CD8a and can potentially contribute to IFNg responses (Vremec et al, 2007; Shortman and Heath, 2010) , the antigen dependence of the observed responses, both at the level of in vivo vaccination and in vitro restimulation, indicated that the responding cells were most likely CD8a þ T cells. Similarly, enumeration of CD8a þ cells spontaneously producing intracellular IFNg (i.e., as a result of in vivo treatment but without in vitro restimulation) in peripheral blood samples by flow cytometry showed a significantly higher response in mice treated with I-aGC-LM-Mb compared to mice treated with LM-Mb or aGC alone ( Figure 6B ). In primary tumours, the percentage of CD8a þ cells producing intracellular IFNg þ was significantly higher for mice that received I-aGC-LMMb compared to mice that received saline, but not compared to mice that received LM-Mb or aGC alone (Supplementary Figure  S4) . In summary, these results were consistent with a superior effect of I-aGC-LM-Mb on stimulating the cross-priming of CD8a þ T cells specific for TAAs. We also measured NK-cell (DX5 þ ) responses in the spleens of I-aGC-LM-Mb-treated and control mice. For this purpose, we infected the spleen cells with LM in vitro and determined the percentage of IFNg-producing cells by ELISPOT with and without anti-DX5 magnetic bead depletion. We found that the number of cells secreting IFNg in response to restimulation by LM infection was significantly increased in I-aGC-LM-Mb-treated mice compared to mice treated with saline, or with LM-Mb or aGC alone. These responses were substantially reduced by depletion of DX5 þ cells, consistent with a large NK-cell component ( Figure 6C ). Overall, our results indicated that treatment of tumour-bearing mice with combined therapy in the form of I-aGC-LM-Mb gave superior CD8a þ T-cell priming against specific TAAs and also enhanced NK cell activation.
Accumulation of I-aGC-LM-Mb in metastases and primary tumours. Previous studies showed enhanced survival and replication of LM in primary and metastatic tumours compared to normal tissues, most likely as a consequence of local immune suppression in the TME Quispe-Tintaya et al, 2013) . To assess the impact of aGC incorporation on survival and replication of I-aGC-LM-Mb in tissues, we analysed bacterial loads in the metastases, tumours, spleens and livers at days 1, 3 and 6 after a single administration of either LM-Mb or I-aGC-LM-Mb (0.5 Â 10 7 CFU; Supplementary Table S2 ). This showed that both LM-Mb and I-aGC-LM-Mb accumulated and persisted at high levels in primary tumour and metastatic tissues, with higher CFU per gram of tissue than in spleen and liver. Incorporation of aGC showed modest reductions in CFU in some cases at day 1 (spleen and liver) and day 3 (spleen), but by day 6 these differences were no longer apparent. We thus conclude that incorporation of aGC into I-aGC-LM-Mb does not significantly diminish its ability to persist and replicate within tumours and metastases.
DISCUSSION
Although treatment with aGC as a free glycolipid injection has shown remarkable anti-tumour activity in a variety of mouse models of cancer, phase I clinical trials of this approach in human cancer patients have not shown clear evidence of therapeutic benefit (Schneiders et al, 2011) . In the study presented here, we have explored various therapeutic approaches using aGC and a LM-based tumour vaccine expressing TAA Mage-b to achieve strong synergistic effects, particularly in the suppression of metastatic disease. In one approach, the LM-Mb vaccine and aGC were administered as separate components, while an alternate strategy used direct incorporation of aGC into live LM-Mb prior to injection into tumour-bearing animals. This latter approach has been used successfully in previous work to improve the vaccine efficacy of live M. bovis BCG (Venkataswamy et al, 2009) . The combination of LM-Mb and aGC, with the glycolipid administered either as a separate series of injections or directly incorporated into the LM-Mb bacteria, was highly effective at reducing the number of metastases, and almost completely eliminated grossly visible metastatic nodules. Most significantly, while the administration of LM-Mb and aGC as separate injections in sequential manner was associated with marked toxicity due to hepatic necrosis, we found that the direct incorporation of the glycolipid into LM-Mb completely eliminated the toxicity while still preserving the marked clinical benefit.
The apparent synergy that we observed between LM and aGC of inducing anti-tumour immunity without toxicity is likely to be related to the incorporation of aGC into the LM-Mb. It is likely that the high efficiency of infection of CD8a þ DC by LM resulted in enhanced intracellular concentration of aGC compared to the uptake of free aGC, and may have improved the activation of NKT cells compared to free aGC in vivo. Indeed, we found that I-aGC-LM-Mb significantly increased the population of NKT cells in the spleen compared to free aGC in 4T1 tumour-bearing mice in vivo. Activated NKT cells are known for producing multiple cytokines, such as IL-2, IFNg and IL-4 that can lead to an immunestimulating environment (Bendelac et al, 2007) . We found that I-aGC-LM-Mb stimulated iNKT-cell hybridoma cells in vitro, and when injected into mice, I-aGC-LM-Mb rapidly induced elevated levels of IFNg and IL-4 in the serum consistent with direct activation of iNKT cells in vivo.
In addition to directly activating iNKT cells, we also found that repeated immunisations of 4T1 tumour-bearing mice with I-aGC-LM-Mb significantly increased the percentage of CD8a þ cells producing IFNg, compared to LM-Mb or aGC alone in vivo. Restimulation in vitro with Mage-b also demonstrated that antigen-specific CD8 þ T-cell responses were significantly enhanced in spleens of mice that received I-aGC-LM-Mb compared to mice that received LM-Mb or free aGC. The 4T1 metastases and primary tumour highly express Mage-b (Kim et al, 2008) and are therefore a target for Mage-b-specific CD8 þ T cells. It has been shown that LM also infects a variety of tumour cells in vitro and in vivo (Kim et al, 2009 ). This converts poorly immunogenic tumour cells into sensitised targets for LM-activated CD8 T and NK cells, and partly explains why unmodified LM also has a considerable anti-metastatic effect. Moreover, we found that LM could be used for the selective delivery of anti-cancer agents such as rapidly decaying radioisotopes to the metastases (QuispeTintaya et al, 2013) . We demonstrated that LM was rapidly cleared in normal tissues by the immune system but prevented from elimination in the TME by the strong immune suppression. Therefore, it is likely that in the current study I-aGC-LM-Mb has delivered aGC to metastases as well, and may have attracted NKT cells selectively to these sites. Consistent with this, we found that the number of CFU of I-aGC-LM-Mb per gram of tissue was significantly higher (14-to 34-fold) in the metastases than in the spleens or livers of tumour-bearing mice. In preliminary experiments, we observed that this was correlated with an approximately two-to three-fold enrichment of the frequency of NKT cells in metastases compared to spleen in mice that received I-aGC-LMMb (unpublished results).
Our results raise the question of why I-aGC-LM-Mb was more effective against the metastases than primary tumours. In a previous study, we found that the percentage of MDSC was much higher in blood (up to B80% of circulating leukocytes) than in the primary tumour (B6% of tumour infiltrating leukocytes) in the 4T1 model and in human cancer patients (Diaz-Montero et al, 2009; Chandra et al, 2013) . Since metastases of 4T1 spread via the blood stream and Listeria infects the MDSC, delivery of I-aGC-LM-Mb to the metastases through MDSC may have been more efficient than to the primary tumour. Indeed, the number of CFU of I-aGC-LM-Mb was significantly higher in metastases than primary tumour on day 1 after injection of the bacteria that may have led to a greater accumulation of NKT cells in metastases compared to primary tumours.
In summary, we have demonstrated that a novel combination of a recombinant LM expressing Mage-b modified by direct incorporation of the NKT-cell-activating glycolipid aGC almost completely eliminated metastases in the 4T1 model without apparent toxicity. This correlated with the activation of NKT cells, NK cells and Mage-b-specific CD8a þ T cells in tumour-bearing mice. The results described here provide a foundation for future studies that could combine a method targeting primary tumours, such as surgery or local radiation therapy, with anti-metastatic treatment using I-aGC-LM-Mb as an approach to achieve prolonged remission or cure of aggressive breast cancer, and perhaps of other metastatic cancers.
